1. Medicines
  2. Ophthalmology
  3. ▼ BEOVU® (brolucizumab)

Prescribing information

▼ Beovu® (brolucizumab)

Beovu is indicated in adults for the treatment of neovascular (wet) AMD.1

 

AMD, age-related macular degeneration.

Reference

  1. Beovu Summary of Product Characteristics, 2020.
BEO20-C039j June 2020.
Ophthalmology
Product
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]